Second-line therapy for refractory renal-cell carcinoma

Critical Reviews in Oncology/Hematology

Volumn 83, Issue 1, 2012, Pages 112-122

  Zustovich, Fable ^a   Lombardi, Giuseppe ^a   Nicoletto, Ornella ^a   Pastorelli, Davide ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Cancer; Kidney; Progression; Target; Therapy

Indexed keywords

ALPHA2A INTERFERON; AXITINIB; BEVACIZUMAB; CYTOKINE; EVEROLIMUS; INTERFERON; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCLONAL ANTIBODY; PAZOPANIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT INTERLEUKIN 2; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN INHIBITOR;

ADVANCED CANCER; ASCITES; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM INFECTION; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONFUSION; CONGESTIVE HEART FAILURE; DIARRHEA; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DUODENUM PERFORATION; DYSPNEA; EVIDENCE BASED MEDICINE; FATIGUE; GASTROINTESTINAL TOXICITY; GOUT; HAIR COLOR; HAND FOOT SYNDROME; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPOPHOSPHATEMIA; INFECTION; INTUSSUSCEPTION; KIDNEY CARCINOMA; KIDNEY METASTASIS; LYMPHOCYTOPENIA; MOLECULARLY TARGETED THERAPY; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PNEUMONIA; PRIMARY HEALTH CARE; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; STOMATITIS; TREATMENT DURATION; TREATMENT PLANNING;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; CYTOKINES; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84862140730     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2011.08.008     Document Type: Review

References (80)

1. Levi F., Ferlay J., Galeone C., et al. The challenge pattern of kidney cancer incidence and mortality in Europe. BJU Int 2008, 101(8):949-958.
2. Pascual D., Bourque A. Epidemiology of kidney cancer incidence and mortality in Europe. Adv Urol 2008, Article ID 782381. 10.1155/2008/782381.
3. Bellmunt J., Fishmann M., Eisen T., Quin D. Expert opinion of the use of first line of sorafenib in selected metastatic renal cell carcinoma patients. Exp Rev Anticancer Ther 2010, 10(6):825-835.
4. Garcia J.A., Rini B.I. Recent progress in the management of advanced renal cell carcinoma. CA Cancer J Clin 2007, 57(2):112-125.
5. Rini B.I., Campbell S.C., Escudier B. Renal cell carcinoma. Lancet 2009, 373:1119-1132.
6. Kim W.Y., Kaelin W.G. Role of VHL gene mutation in human cancer. J Clin Oncol 2004, 22(24):4991-5004.
7. Thomas G.V., Tran C., Mellinghoff I.K., et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006, 12(1):122-127.
8. Sternberg C.N., Davis I.D., Mardiak J. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010, 28(6):1061-1068.
9. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356(22):2271-2281.
10. Escudier B., Bellmunt J., Négrier S., et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010, 28(13):2137-2143.
11. Rini B.I., Halabi S., Rosenberg J.E., et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008, 26(33):5422-5428.
12. Oudard S., Ravaud A., Escudier B. Sequencing of therapeutic agents in the treatment of advanced renal cell carcinoma: focus on mechanism of action. Ann Urol 2010, http://www.slm-urology.com/.
13. Sutent EMEA label.
14. Sutent FDA label.
15. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
16. Gore M.E., Szczylik C., Porta C., et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009, 10(8):757-763.
17. Kwitkowski V.E., Prowell T.M., Ibrahim A., et al. FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma. Oncologist 2010, 15:428-435.
18. Torisel EMEA label.
19. Avastin FDA label.
20. Avastin EMEA label.
21. Votrient EMEA label.
22. Votrient FDA label.
23. Pazopanib versus sunitinib in the treatment of locally advanced and/or metastatic renal cell carcinoma. Available from: [accessed 25.11.10]. http://www.clinicaltrials.gov/.
24. Nexavar FDA label.
25. Nexavar EMEA label.
26. Halbert R.J., Figlin R.A., Atkins M.B., et al. Treatment of patients with metastatic renal cell cancer: a RAND appropriateness panel. Cancer 2006, 107(10):2375-2383.
27. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Kidney Cancer. V.2.2010. Available from: [accessed 14.04.10]. http://www.nccn.org/.
28. Yang J.C., Sherry R.M., Steinberg S.M., Topalian S.L., Schwartzentruber D.J., Hwu P. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003, 21:3127-3132.
29. Kirchner H., Strumberg D., Bahl A., Overkamp F. Patient-based strategy for systemic treatment of metastatic renal cell carcinoma. Expert Rev Anticancer Ther 2010, 10(4):585-596.
30. Coppin C., Porzsolt F., Autenrieth M., Kumpf J., Coldman A., Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev Issue 2000, 3. Art. No.: CD001425. 10.1002/14651858.
31. Escudier B., Chevreau C., Lasset C., et al. Cytokines in metastatic renal cell carcinoma: is it useful to switch to minterleukin-2 or interferon after failure of a first treatment?. J Clin Oncol 1999, 17:2039-2043.
32. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
33. Bukowski R.M., Stadler W.M., McDermott D.F., et al. Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program. Oncology 2010, 78(5-6):340-347.
34. Stadler W.M., Figlin R.A., McDermott D.F., et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America; ARCCS Study Investigators. Cancer 2010, 116(5):1272-1280.
35. Beck J., Procopio G., Negrier S., et al. Final analysis of a large, open-label, noncomparative study of sorafenib in European patients with advanced RCC (EU-ARCCS). Eur J Cancer Suppl 2009, 7(2):434. Abstract P-7137.
36. Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006, 295(21):2516-2524.
37. Escudier B., Roigas J., Gillessen S., et al. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 2009, 27(25):4068-4075.
38. Hutson T.E., Davis I.D., Machiels J.P., et al. Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): interim results of a phase II randomized discontinuation trial (RDT). J Clin Oncol 2007, 25. [suppl; abstr 5031].
39. Hutson T.E., Davis I.D., Machiels J.P., et al. Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multikinase angiogenesis inhibitor. J Clin Oncol 2008, 26. [suppl; abstr 5046].
40. Sternberg C.N., Szczylik C., Lee E., et al. A randomized, double-blind phase III study of pazopanib in treatment-naïve and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J Clin Oncol 2009, 27. [suppl; abstr 5021].
41. Di Lorenzo G., Cartenì G., Autorino R., et al. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol 2009, 27(27):4469-4474.
42. Mancuso A.P., De Paola E.D., Catalano A., et al. Phase II dose escalation study of sorafenib in patients with metastatic renal cell carcinoma (mRCC) who have had prior treatment with VEGFR-TKI antiangiogenic treatment. J Clin Oncol 2009, 27. [suppl; abstr 16027].
43. Sepulveda J., Maroto P., Andres R., et al. Sorafenib as a second-line and sequential therapy for patients with metastatic renal cell carcinoma (mRCC): analysis for safety and activity of sunitinib progressive pts. J Clin Oncol 2008, 26. [suppl; abstr 16100].
44. Garcia J.A., Hutson T.E., Elson P., Cowey C.L., Gilligan T., Nemec C. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Cancer 2011, 16(23):5383-5390.
45. ClinicalTrials.gov Web site. SWITCH trial: sequential study to treat renal cell carcinoma. Available from: [accessed November 25]. http://www.clinicaltrials.gov/.
46. Zimmermann K., Schmittel A., Steiner U., et al. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology 2009, 76:350-354.
47. Rini B.I., Michaelson M.D., Rosenberg J.E., et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008, 26(22):3743-3748.
48. Pastorelli D., Zustovich F., Faggioni G., et al. Good response to second-line bevacizumab and interferon-a in a sunitinib-refractory patient with metastatic renal cell carcinoma. Anticancer Drugs 2010, 21(2):210-213.
49. Agostino N.M., Gingrich R., Draibick J. Bevacizumab demonstrates prolonged disease stabilization in patients with heavily pretreated metastatic renal cell carcinoma: a case series and review of the literature. Adv Urol 2010, Article ID 687043. 10.1155/2010/687043.
50. Rixe O., Bukowski R.M., Michaelson M.D., et al. Axitinib treatment in patients with cytokine refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007, 8:975-984.
51. Rini B.I., Wilding G., Hudes G., et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009, 27(27):4462-4468.
52. ClinicalTrials.gov Web site. Axitinib (AG 013736) as second line therapy for metastatic renal cell cancer. Available from: [accessed 21.06.10]. http://www.clinicaltrials.gov/.
53. Afinitor FDA label.
54. Afinitor EMEA label.
55. Motzer R.J., Escudier B., Oudard S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456.
56. Motzer R.J., Escudier B., Oudard S., et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma. Cancer 2010, 116:4256-4265.
57. Bojanapally P.R., Graham S., Rustine, Sacris L.A., Dutcher J.P. Temsirolimus for advanced renal cell carcinoma (RCC): compassionate versus commercial use. J Clin Oncol 2008, 26. [suppl; abstr 16139].
58. Schmidinger M., Vogl U.M., Lamm W., Bojic M., Bojic A., Zielinski C.C. Temsirolimus in heavily pre-treated patients with metastatic renal cell carcinoma: preliminary results from the Austrian Compassionate Use Program. J Clin Oncol 2008, 26. [suppl; abstr 16125].
59. Gerullis H., Bergman L., Maute L., et al. Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma. Med Oncol 2010, 27:373-378.
60. MacKenzie M.J., Rini B.I., Elson P., et al. Temsirolimus in VEGF-refractory metastatic renal cell carcinoma. Ann Oncol 2010, (July):1. [Epub ahead of print].
61. ClinicalTrials.gov Web site. Bevacizumab, sorafenib, and temsirolimus in treating patients with metastatic kidney cancer. Available from: [accessed 25.11.10]. http://www.clinicaltrials.gov/.
62. Di Lorenzo G., Buonerba C., Federico P., et al. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. Eur Urol 2010, September 24 [E-pub ahead of print].
63. Ferrari V.D., Fogazzi G., Valcamonico F., et al. III-IV line of target therapy in advanced renal cell carcinoma (RCC). J Clin Oncol 2010, 28. [suppl; abstr e15148].
64. Richter S., Pfister D., Thuer D., Engelmann U.H., Heidenreich A. Second-line treatment of progressive metastatic renal cell cancer with temsirolimus following first-line therapy with sunitinib or sorafenib. DGHO Deutsche Gesellschaft fur Hamatologie und Onkologie. Onkologie 2008, 31(Suppl. 4):234. [abstr V684].
65. Shaheen P.E., Rini B.I., Bukowski R.M. Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports. Clin Genitourin Cancer 2006, 5(1):78-81.
66. Rini B.I., Zama I.N., Hutson T.E., et al. Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer 2010, 116(23):5400-5406. 10.1002/cncr.25583.
67. Dandamudi U.B., Ghebremichael M.S., Sosman J.A. A phase II study of bevacizumab (B) and high-dose aldesleukin (IL-2) in patients (p) with metastatic renal cell carcinoma (mRCC): a Cytokine Working Group Study (CWGS). Journal of Clinical Oncology 2010, 28:15s. [suppl; abstr 4530].
68. Escudier B.J., Negrier S., Gravis G., Chevreau C. Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial. J Clin Oncol 2010, 28:15s. [suppl; abstr 4516].
69. Available from: . http://www.asco.org/ASCOv2/MultiMedia/Virtual+Meeting%3F%26vmview=vm_session_presentations_view%26confID=74%26trackID=15%26sessionID=3293.
70. Porta C., Paglino C., Imarisio I. Sequencing tyrosine kinase inhibitors or immediately switching to mTOR inhibitors in advanced kidney cancer: a critical review. EJCMO 2010, 2(3).
71. Ljungberg B., Cowan N.C., Hanbury D.C., et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010, 58(3):29-38.
72. Procopio G., Verzoni E., Gevorgyan A., et al. Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma. Oncology 2007, 73:204-209.
73. Choueiri T.K., Plantade A., Elson P., et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008, 26(1):1.
74. Vickers M.M., Choueiri T.K., Rogers M., et al. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology 2010, 76(2):430-434.
75. Dudek A.Z., Zolnierek J., Dham A., Lindgren B.R., Szczylik C. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 2009, 115:61-67.
76. Sablin M.P., Negrier S., Ravaud A., et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol 2009, 182:29-34.
77. Tamaskar I., Garcia J.A., Elson P., et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 2008, 179:81-86.
78. Eichelberg C., Heuer R., Chun F.K., et al. Sequential use of the tyrosine kinase inhibitor sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur Urol 2008, 54:1373-1378.
79. Choueiri T.K., Brick A.J., McDermott S. Treatment dosing patterns for angiogenesis inhibitors (AIS) therapies in patients with metastatic renal cell carcinoma (MRCC). Ann Oncol 2008, 19(Suppl. 8):593.
80. ClinicalTrials.gov Web site. Study comparing bevacizumab+temsirolimus vs. bevacizumab+interferon-alfa in advanced renal cell carcinoma subjects (INTORACT). Available from: [accessed 21.04.11]. http://www.clinicaltrials.gov/.